Table 4.
Available data about advanced ACC therapy.
| Subtype | Study type | Drug | Number of patients | ORR (%) | mPFS, months | References |
|---|---|---|---|---|---|---|
| ACC | Phase Ib | Pembrolizumab | 2 | 0 | 4 | (52) |
| ACC | Phase I/II | Pembrolizumab + vorinostat | 12 | 0 | 7 | (55) |
| ACC | Phase II | Cetuximab | 23 | 0 | 3.0 | (59) |
| ACC | Phase II | Gefitinib | 18 | 0 | 4.3 | (60) |
| ACC | Phase II | Sorafenib | 19 | 0 | 11.3 | (69) |
| ACC | Phase II | Sorafenib | 19 | 0 | 8.9 | (62) |
| ACC | Phase II | Axitinib | 33 | 0 | 5.7 | (70) |
| ACC | Phase II | Regorafenib | 38 | 0 | N/A | (71) |
| ACC | Phase II | Lenvatinib | 28 | 0 | 9.0 | (72) |
| ACC | Phase II | Lenvatinib | 32 | 0.2 | 17.5 | (73) |
| ACC | Phase II | Nintedanib | 65 | 0 | 8.2 | (64) |
| ACC | Phase II | Dovitinib | 34 | 0 | 8.2 | (74) |
| ACC | Phase II | Imatinib | 16 | 0 | N/A | (75) |
| ACC | Phase II | Imatinib | 17 | 0 | N/A | (76) |
| ACC | Phase II | Dasatinib | 40 | 0 | 4.8 | (65) |
| ACC | Phase II | Lapatinib | 33 | 0 | 3.5 | (58) |
| ACC | Phase II | Everolimus | 34 | 0 | 11.2 | (77) |
| ACC | Phase II | Bortezomib + doxorrubicina | 24 | 0,04 | 6.4 | (78) |
| ACC | Phase I | GSK3326595** | 14 | 0.2 | N/A | (79) |
| ACC | Phase II | Vorinostat | 30 | 0.7 | 7,7 | (80) |
| ACC | Phase I | Bronticizumab | 12 | 0.2 | N/A | (81) |
| ACC | Phase Ib/II | Amcasertib (BBI503)** | 14 | 0 | 6.1 | (82) |
| ACC | Phase I | AL101 | 2 | 0 | 8 | (83) |
| ACC | Phase I | Crenigacestat (LY3039478) | 22 | 0 | 5.3 | (84) |
**
Trials ongoing with preliminary results.